CLINICAL_TRIALS
trial_result
· 2021-07-15
Clinical Trial Update: Alvocidib Biomarker-driven Phase 2 AML Study [Phase 2]
Summary
A Phase 2, biomarker-driven trial of alvocidib in acute myeloid leukemia was terminated; results were posted in 2021.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Sumitomo Pharma America, Inc. | Conditions: Acute Myeloid Leukemia | Phase 2 | Status: TERMINATED | Results posted: 2021-07-15